1-3 of 3
Christian Mueller
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma

Martin Forster, Irene Brana, Antonio L. Pousa, Bernard Doger, Patricia Roxburgh, Pawan Bajaj, Julio Peguero, Matthew Krebs, Enric Carcereny, Grisma Patel, Christian Mueller, Chrystelle Brignone, Frederic Triebel
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3726–3734.
https://doi.org/10.1158/1078-0432.CCR-24-0473
Published: 03 September 2024
View article titled, Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma
Open the PDF for Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial

Hans Wildiers, Anne Armstrong, Eveline Cuypere, Florence Dalenc, Luc Dirix, Steve Chan, Frederik Marme, Carolina P. Schröder, Jens Huober, Francois P. Duhoux, Peter Vuylsteke, Agnes Jager, Etienne Brain, Sherko Kuemmel, Zsuzsanna Pápai, Catharina Willemien Menke-van der Houven van Oordt, Luca Perjesi, Christian Mueller, Chrystelle Brignone, Frederic Triebel
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (3): 532–541.
https://doi.org/10.1158/1078-0432.CCR-23-1173
Published: 01 February 2024
View article titled, Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR<sup>+</sup> Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial
Open the PDF for Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR<sup>+</sup> Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial in another window
Includes: Supplementary data
Journal Articles

Phase I and Pharmacokinetic Study of the Polyamine Synthesis Inhibitor SAM486A in Combination with 5-Fluorouracil/ Leucovorin in Metastatic Colorectal Cancer

Lia van Zuylen, John Bridgewater, Alex Sparreboom, Ferry A. L. M. Eskens, Peter de Bruijn, Ivo Sklenar, Andre S. T. Planting, Les Choi, Douglas Bootle, Christian Mueller, Jonathan A. Ledermann, Jaap Verweij
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (6): 1949–1955.
https://doi.org/10.1158/1078-0432.CCR-02-0995
Published: 24 March 2004
View article titled, Phase I and Pharmacokinetic Study of the Polyamine Synthesis Inhibitor SAM486A in Combination with 5-Fluorouracil/ Leucovorin in Metastatic Colorectal Cancer
Open the PDF for Phase I and Pharmacokinetic Study of the Polyamine Synthesis Inhibitor SAM486A in Combination with 5-Fluorouracil/ Leucovorin in Metastatic Colorectal Cancer in another window